Supplementation with a low-moderate dose of n-3 long-chain PUFA has no short-term effect on bone resorption in human adults

This data was imported from PubMed:

Authors: Appleton, K.M., Fraser, W.D., Rogers, P.J., Ness, A.R. and Tobias, J.H.

Journal: Br J Nutr

Volume: 105

Issue: 8

Pages: 1145-1149

eISSN: 1475-2662

DOI: 10.1017/S0007114510004861

Previous research suggests that n-3 PUFA may play a role in bone health. The present analysis aimed to investigate the impact of n-3 PUFA supplementation on bone resorption in adult men and women. Serum samples from 113 mild-moderately depressed individuals (twenty-six males and eighty-seven females, aged 18-67 years) randomised to receive 1·48 g EPA+DHA/d (n 53) or placebo (n 60) for 12 weeks as part of a large recent randomised controlled trial were assayed for n-3 PUFA status and a bone resorption marker, C-terminal cross-linking telopeptide of type 1 collagen (β-CTX). Regression analyses revealed that n-3 PUFA status following supplementation was associated with randomisation (placebo/n-3 PUFA) (B = 3·25, 95 % CI 2·60, 3·91, P < 0·01). However, β-CTX status following supplementation was not associated with randomisation (B = - 0·01, 95 % CI - 0·03, 0·04). Change in β-CTX status was also not associated with change in n-3 PUFA status (B = - 0·002, 95 % CI - 0·01, 0·01). These findings provide no evidence for an association between n-3 PUFA supplementation (1·48 g EPA+DHA/d) for 12 weeks and bone resorption in humans assessed by β-CTX, and suggest that n-3 PUFA supplementation may be unlikely to be of benefit in preventing bone loss.

This source preferred by Katherine Appleton

This data was imported from Scopus:

Authors: Appleton, K.M., Fraser, W.D., Rogers, P.J., Ness, A.R. and Tobias, J.H.

Journal: British Journal of Nutrition

Volume: 105

Issue: 8

Pages: 1145-1149

eISSN: 1475-2662

ISSN: 0007-1145

DOI: 10.1017/S0007114510004861

Previous research suggests that n-3 PUFA may play a role in bone health. The present analysis aimed to investigate the impact of n-3 PUFA supplementation on bone resorption in adult men and women. Serum samples from 113 mild-moderately depressed individuals (twenty-six males and eighty-seven females, aged 18-67 years) randomised to receive 1·48g EPA+DHA/d (n 53) or placebo (n 60) for 12 weeks as part of a large recent randomised controlled trial were assayed for n-3 PUFA status and a bone resorption marker, C-terminal cross-linking telopeptide of type 1 collagen (β-CTX). Regression analyses revealed that n-3 PUFA status following supplementation was associated with randomisation (placebo/n-3 PUFA) (B=325, 95% CI 2·60, 3·91, P<0·01). However, β-CTX status following supplementation was not associated with randomisation (B=-0·01, 95 % CI -0·03, 0·04). Change in β-CTX status was also not associated with change in n-3 PUFA status (B=-·002, 95% CI -0·01, 0·01). These findings provide no evidence for an association between n-3 PUFA supplementation (1·48g EPA+DHA/d) for 12 weeks and bone resorption in humans assessed by β-CTX, and suggest that n-3 PUFA supplementation may be unlikely to be of benefit in preventing bone loss. © 2010 The Authors.

This data was imported from Web of Science (Lite):

Authors: Appleton, K.M., Fraser, W.D., Rogers, P.J., Ness, A.R. and Tobias, J.H.

Journal: BRITISH JOURNAL OF NUTRITION

Volume: 105

Issue: 8

Pages: 1145-1149

ISSN: 0007-1145

DOI: 10.1017/S0007114510004861

This data was imported from Europe PubMed Central:

Authors: Appleton, K.M., Fraser, W.D., Rogers, P.J., Ness, A.R. and Tobias, J.H.

Journal: The British journal of nutrition

Volume: 105

Issue: 8

Pages: 1145-1149

eISSN: 1475-2662

ISSN: 0007-1145

Previous research suggests that n-3 PUFA may play a role in bone health. The present analysis aimed to investigate the impact of n-3 PUFA supplementation on bone resorption in adult men and women. Serum samples from 113 mild-moderately depressed individuals (twenty-six males and eighty-seven females, aged 18-67 years) randomised to receive 1·48 g EPA+DHA/d (n 53) or placebo (n 60) for 12 weeks as part of a large recent randomised controlled trial were assayed for n-3 PUFA status and a bone resorption marker, C-terminal cross-linking telopeptide of type 1 collagen (β-CTX). Regression analyses revealed that n-3 PUFA status following supplementation was associated with randomisation (placebo/n-3 PUFA) (B = 3·25, 95 % CI 2·60, 3·91, P < 0·01). However, β-CTX status following supplementation was not associated with randomisation (B = - 0·01, 95 % CI - 0·03, 0·04). Change in β-CTX status was also not associated with change in n-3 PUFA status (B = - 0·002, 95 % CI - 0·01, 0·01). These findings provide no evidence for an association between n-3 PUFA supplementation (1·48 g EPA+DHA/d) for 12 weeks and bone resorption in humans assessed by β-CTX, and suggest that n-3 PUFA supplementation may be unlikely to be of benefit in preventing bone loss.

The data on this page was last updated at 04:53 on March 24, 2019.